Table III.
Time post-immunotherapy (months) | ||||||
---|---|---|---|---|---|---|
Lymphocyte subset | Pre-immunotherapy | 1 | 3 | 6 | 9 | 12 |
CD3+ | 0.711 | 0.000a | 0.371 | 0.432 | 0.436 | 0.462 |
CD8+ | 0.843 | 0.115 | 0.026a | 0.092 | 0.115 | 0.774 |
CD8+CD28+ | 0.323 | 0.004a | 0.036a | 0.873 | 0.022a | 0.607 |
NKT | 0.793 | 0.038a | 0.771 | 0.160 | 0.038a | 0.004a |
CD8+CD28− | 0.585 | 0.432 | 0.777 | 0.326 | 0.471 | 0.948 |
CD4+CD25+ | 0.915 | 0.544 | 0.024b | 0.025b | 0.795 | 0.629 |
CD4+CD8+ | 0.743 | 0.585 | 0.008b | 0.065 | 0.359 | 0.879 |
CD4+ | 0.674 | 0.053 | 0.027b | 0.278 | 0.480 | 0.311 |
CD3+CD16+CD56+ (NK) | 0.647 | 0.201 | 0.694 | 0.875 | 0.750 | 0.642 |
CD19+ | 0.763 | 0.057 | 0.817 | 0.529 | 0.289 | 0.706 |
T lymphocyte subgroup is higher in patients receiving immunotherapy compared with the control group
T lymphocyte subgroup is lower in patients receiving immunotherapy group compared with the control group. NK, natural killer.